Lilly Commits $1.2B to Transform Oral Therapy Landscape with Ventyx Acquisition

Eli Lilly and Company today announced it will buy Ventyx Biosciences for approximately $1.2 billion in cash, a deal that aims to broaden Lilly’s reach into oral medicines for inflammation and related diseases. The acquisition adds a promising pipeline of small molecule therapies to Lilly’s portfolio, and the deal is expected to close in the first half of 2026, pending approvals. Lilly will pay $14 per share in cash to Ventyx stockholders, reflecting a significant premium over recent trading levels.

$1.2B Deal Brings Oral Therapy Expertise to Lilly

The all-cash acquisition gives Lilly full ownership of Ventyx’s clinical-stage pipeline, allowing the company to directly integrate its oral immunology programs into Lilly’s broader research and development strategy. This move strengthens Lilly’s capabilities beyond its existing immunology and metabolic products by bringing in Ventyx’s clinical-stage oral therapy pipeline.

The purchase price represents about a 62% premium over Ventyx’s recent average share price, signaling Lilly’s confidence in the long-term potential of Ventyx’s science despite recent volatility in the biotech market. Lilly anticipates completing the acquisition in the first half of this year, subject to approval by Ventyx stockholders and typical closing requirements, including regulatory reviews.

For Lilly, the acquisition reflects a deeper push into oral small molecule therapies for immune-mediated and inflammatory diseases and cardiometabolic conditions, where many patients still rely on injectable biologics. For Ventyx, it offers access to extensive development resources and the potential to accelerate clinical programs for patients living with inflammatory mediated diseases.

Oral Therapies Targeting Inflammation and Beyond

Ventyx has built a diverse portfolio of therapeutic candidates that target chronic inflammation and immune pathways. These include class-leading NLRP3 inhibitors and multiple small molecules designed to provide oral treatment options for conditions like ulcerative colitis, Crohn’s disease, and other chronic inflammatory disorders that are commonly treated with injectable biologics or infusion-based therapies that currently rely on injectable or complex biologic drugs.

Inflammation is now recognized as a driver in many long-term health conditions, from inflammatory bowel disease and autoimmune disorders to cardiometabolic and neurodegenerative diseases.Ventyx’s pipeline centers on small molecule inhibitors that target key immune signaling pathways, including NLRP3 inflammasome activity, which plays a role in driving chronic inflammation across multiple diseases. By acting on these intracellular pathways, the company aims to deliver oral therapies that are easier to administer and potentially more consistent for long-term disease management.

Daniel M. Skovronsky, Lilly’s chief scientific officer, noted the importance of inflammation in chronic disease and described how Ventyx’s pipeline could play a critical role in advancing treatment options across multiple disease categories. At the same time, Ventyx’s CEO, Raju Mohan, emphasized Lilly’s resources and strategic alignment as a strong platform to advance novel oral therapies that address unmet patient needs.

Strategic Impact for Patients and the Market

The deal comes as competition intensifies in the inflammatory disease market, where conditions such as inflammatory bowel disease and autoimmune disorders affect millions worldwide. While biologic drugs have transformed care over the past two decades, their high cost and injectable delivery have driven growing interest in oral small molecule alternatives. By bringing Ventyx into its pipeline, Lilly positions itself to compete more aggressively in this evolving treatment landscape once the transaction closes in early 2026.

Author

[email protected]